ANAHEIM, Calif., July 26 /PRNewswire-FirstCall/ -- A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott (NYSE: ABT ) will highlight at this year's American Association for Clinical Chemistry Lab Expo (AACC) which starts today in Anaheim. In all, Abbott is sponsoring 29 scientific posters reporting on new clinical diagnostics research in areas such as heart disease or cardiac care, transplant, renal disease and cancer; three scientific industry workshops; and 15 main stage presentations at the Abbott exhibit booth (#6808).
"Abbott is focused on improving patient care by offering innovative solutions for our laboratory customers and the patients and physicians they serve," said Brian Blaser, senior vice president, Diagnostics, Abbott. "At this year's AACC, we will feature our latest assays and systems which offer solutions to meet the demanding needs of healthcare institutions by improving operational efficiency, clinical outcomes, and physician, patient, and laboratory satisfaction."
Abbott AACC Highlights
- Advances in HIV Testing Foster Early Detection: Last
month, the FDA approved Abbott's ARCHITECT HIV Antigen/Antibody
Combo Assay, a first-of-its-kind new HIV diagnostic tool. Since the
test detects both HIV antigens and antibodies, Abbott's test can
identify infection days earlier than other an